Clinical Trial Update: Model-informed Dose De-escalation of Infliximab in Patients With Inflammatory Bowel Diseases [Phase 4]

View source ↗

Summary

A Phase 4 study conducted in Belgium evaluates model-informed dose de-escalation of infliximab in patients with inflammatory bowel diseases; the trial has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Bowel Disease

Drugs mentioned

• Remicade (infliximab)

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Inflammatory Bowel Diseases | Phase 4 | Status: COMPLETED